Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0376358 (
prostate cancer
)
59,338
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The androgen receptor (AR) is a ligand-dependent transcription factor that promotes
prostate cancer
(PC) cell growth through control of target gene expression. This report suggests that Canopy FGF signaling regulator 2 (CNPY2) controls AR protein levels in PC cells. We found that AR was ubiquitinated by an E3 ubiquitin ligase,
myosin regulatory light chain interacting protein
(
MYLIP
) and then degraded through the ubiquitin-proteasome pathway. CNPY2 decreased the ubiquitination activity of
MYLIP
by inhibition of interaction between
MYLIP
and UBE2D1, an E2 ubiquitin ligase. CNPY2 up-regulated gene expression of AR target genes such as
KLK3
gene which encodes the prostate specific antigen (PSA) and promoted cell growth of PC cells. The cell growth inhibition by CNPY2 knockdown was rescued by
AR
overexpression. Furthermore, positive correlation of expression levels between CNPY2 and AR/AR target genes was observed in tissue samples from human
prostate cancer
patients. Together, these results suggested that CNPY2 promoted cell growth of PC cells by inhibition of AR protein degradation through
MYLIP
-mediated AR ubiquitination.
...
PMID:CNPY2 inhibits MYLIP-mediated AR protein degradation in prostate cancer cells. 2970 37